Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 101–200 of 1,008
Greter, M., Helft, J., Chow, A., Hashimoto, D., Mortha, A., Agudo-Cantero, J., Bogunovic, M., Gautier, E. L., Miller, J., Leboeuf, M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.027 · Cited by 433
“, 2009) and are dependent on Flt3 ligand (Flt3L) and on the transcription factors Batf3, IRF8, and Id2 for their development (Edelson et al., 2010; Ginhoux et al., 2009; Hashimoto et al., 2011b; Hildner et al., 2008).”
BackgroundInfluentialAntigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses
Hilligan, K. L., & Ronchese, F. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0465-0 · Cited by 430
“This may explain why cDC2, which are superior at taking up exogenous antigen, are pivotal in directing Th cell differentiation in many settings, whereas cDC1, which specialize in the uptake of cell-associated antigen,(103) excel at cross-presentation.(28) In addition to pathogen-derived signals, DC also sense signals,…”
BackgroundCross-priming in health and disease
Kurts, C., Robinson, B. W. S., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2780 · Cited by 429
“The targeting of DC subsets has become possible by the discovery that the transcription factor BATF3 (basic leucine zipper transcriptional factor ATF-like 3) is expressed by CD8α + and CD103 + DCs and is necessary for cross-presentatio”
BackgroundGerner, M. Y., Kastenmuller, W., Ifrim, I., Kabat, J., & Germain, R. N. (2012) · Immunity · doi:10.1016/j.immuni.2012.07.011 · Cited by 425
“Batf3 / mice on the 129 background (Hildner et al., 2008) were provided by K. Murphy (University of Washington, St. Louis, MI, USA) and backcrossed to C57BL/6 for two generations.”
BackgroundMethodInfluentialDendritic cell subsets in primary and secondary T cell responses at body surfaces
Heath, W. R., & Carbone, F. R. (2009) · Nature Immunology · doi:10.1038/ni.1822 · Cited by 421
“The migratory CD103 + DCs and the lymphoid tissue–resident CD8α + DCs bear many similarities, including expression of langerin, lack of CD11b, some antigen-presentation functions (discussed below), and their absence in mice deficient in the transcription factor Batf3 (ref”
BackgroundCompensatory dendritic cell development mediated by BATF–IRF interactions
Tussiwand, R., Lee, W.-L., Murphy, T. L., Mashayekhi, M., KC, W., Albring, J. C., Satpathy, A. T., Rotondo, J. A., Edelson, B. T., Kretzer, N. M., et al. (2012) · Nature · doi:10.1038/nature11531 · Cited by 419
Functions of Murine Dendritic Cells
Durai, V., & Murphy, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.010 · Cited by 413
“Batf3 / mice failed to prime CD8 T cells against cell-associated antigen or West Nile virus (WNV), but still had intact priming of CD4 T cells (Hildner et al., 2008).Batf3 / mice alsomounted reduced CD8 T cell responses to cytomegalovirus (CMV) (Torti et al., 2011), influenza (Helft et al., 2012;…”
InfluentialBosteels, C., Neyt, K., Vanheerswynghels, M., van Helden, M. J., Sichien, D., Debeuf, N., De Prijck, S., Bosteels, V., Vandamme, N., Martens, L., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.005 · Cited by 412
Tissue-Specific Immunity at the Oral Mucosal Barrier
Moutsopoulos, N. M., & Konkel, J. E. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.08.005 · Cited by 409
Innate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408
Mashayekhi, M., Sandau, M. M., Dunay, I. R., Frickel, E. M., Khan, A., Goldszmid, R. S., Sher, A., Ploegh, H. L., Murphy, T. L., Sibley, L. D., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.008 · Cited by 403
“CD8+ T cell priming to T. gondii-derived antigens is defective in Batf3−/− mice Since CD8α+ DCs are important for generation of virus-specific CD8+ effector T cells (Hildner et al., 2008), we examined T cell responses in Batf3−/− mice after infection by T. gondii (Figure 2).”
InfluentialZhou, Y., Fei, M., Zhang, G., Liang, W.-C., Lin, W., Wu, Y., Piskol, R., Ridgway, J., McNamara, E., Huang, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.014 · Cited by 399
Henri, S., Poulin, L. F., Tamoutounour, S., Ardouin, L., Guilliams, M., de Bovis, B., Devilard, E., Viret, C., Azukizawa, H., Kissenpfennig, A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091964 · Cited by 402
“Lymphoid tissue–resident CD8+ DCs have become a focus of intensive investigation because they are prone to cross-present antigens, a property important for inducing peripheral tolerance and for fighting infections and tumors (Hildner et al., 2008).”
BackgroundGrajales-Reyes, G. E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., KC, W., Kretzer, N. M., Briseño, C. G., Durai, V., Bagadia, P., et al. (2015) · Nature Immunology · doi:10.1038/ni.3197 · Cited by 399
Specificity through cooperation: BATF–IRF interactions control immune-regulatory networks
Murphy, T. L., Tussiwand, R., & Murphy, K. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3470 · Cited by 399
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
The cis-Regulatory Atlas of the Mouse Immune System
Yoshida, H., Lareau, C. A., Ramirez, R. N., Rose, S. A., Maier, B., Wroblewska, A., Desland, F., Chudnovskiy, A., Mortha, A., Dominguez, C., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.036 · Cited by 395
“Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.”
InfluentialMerad, M., & Manz, M. G. (2009) · Blood · doi:10.1182/blood-2008-12-180646 · Cited by 395
Patente, T. A., Pinho, M. P., Oliveira, A. A., Evangelista, G. C. M., Bergami-Santos, P. C., & Barbuto, J. A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03176 · Cited by 392
“In mice, besides BATF3 (147) and IRF8 (148), gene knockout models pointed out to the role of two other TF: DNA binding protein inhibitor ID2 (149) and nuclear factor interleukin-3-regulated protein (NFIL3) (150), whose participation in the generation of human cDC1 needs yet to be demonstrated.”
BackgroundNew Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis
Wu, M.-Y., Li, C.-J., Hou, M.-F., & Chu, P.-Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102034 · Cited by 392
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 383
“In line with this hypothesis, selective targeting of anti-PD-L1 antibodies to TDLNs (where high PD-L1 expression is mostly found on cDC2s) through intrapleural administration results in effective cancer control in mice, indicating that ICIs can stimulate antitumour effector T cells in TDLNs 144 .”
InfluentialTIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
“129S9C)-Batf3tm1Kmm/J; backcrossed to FVBN/J x5 Hildner et al., 2008 JAX: 013755; RRID: IMSR_JAX:013755 Mouse: FVB-Tg(C3-1-TAg)cJeg/JegJ Maroulakou et al., 1994 JAX: 013591; RRID: IMSR_JAX:013591 Mouse: B6.”
InfluentialCX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22
Longman, R. S., Diehl, G. E., Victorio, D. A., Huh, J. R., Galan, C., Miraldi, E. R., Swaminath, A., Bonneau, R., Scherl, E. J., & Littman, D. R. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140678 · Cited by 383
Ise, W., Kohyama, M., Schraml, B. U., Zhang, T., Schwer, B., Basu, U., Alt, F. W., Tang, J., Oltz, E. M., Murphy, T. L., et al. (2011) · Nature Immunology · doi:10.1038/ni.2037 · Cited by 375
“2037" language="eng" relation="no"> BATF and BATF3, two members of the AP-1 family of transcription factors, provide distinct lineage-specific functions in the immune syste”
Type I interferon response and innate immune sensing of cancer
Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375
“Moreover, Batf3−/− mice, that selectively lack the CD8α+ DC subpopulation, showed an impaired capacity for antigen crosspresentation and anti-viral and anti-tumor CTL responses [28].”
Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372
“To determine whether DC1s were necessary for tumor rejection, we implanted both cell lines into Batf3 / mice lacking DC1s (Hildner et al., 2008).”
BackgroundResultInfluentialTumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance
Liu, Y., Liang, G., Xu, H., Dong, W., Dong, Z., Qiu, Z., Zhang, Z., Li, F., Huang, Y., Li, Y., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.001 · Cited by 361
Dendritic Cell and Macrophage Heterogeneity In Vivo
Hashimoto, D., Miller, J., & Merad, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.007 · Cited by 368
“…have now established that CD8+ DCs arise from a distinct differentiation program that is dependent on key transcription factors that include Batf3 (Hildner et al., 2008) and IRF8 (Aliberti et al., 2003; Schiavoni et al., 2002; Tailor et al., 2008) and the inhibitor of DNA protein Id2 (Hacker et…”
BackgroundNanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Antigen-Presenting Cells in the Skin
Kashem, S. W., Haniffa, M., & Kaplan, D. H. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052215 · Cited by 361
High-dimensional analysis of the murine myeloid cell system
Becher, B., Schlitzer, A., Chen, J., Mair, F., Sumatoh, H. R., Teng, K. W. W., Low, D., Ruedl, C., Riccardi-Castagnoli, P., Poidinger, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.3006 · Cited by 357
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Theisen, D. J., Davidson, J. T., Briseño, C. G., Gargaro, M., Lauron, E. J., Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J. R., et al. (2018) · Science · doi:10.1126/science.aat5030 · Cited by 346
Dendritic cell subsets and locations
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.004 · Cited by 349
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity
Hutton, C., Heider, F., Blanco-Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S., Paulus-Hock, V., Watt, D., Steele, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.017 · Cited by 337
“Rag1-/- mice (Mombaerts et al., 1992) and B6.Batf3-/- mice (Hildner et al., 2008).”
Inflammatory Monocytes Facilitate Adaptive CD4 T Cell Responses during Respiratory Fungal Infection
Hohl, T. M., Rivera, A., Lipuma, L., Gallegos, A., Shi, C., Mack, M., & Pamer, E. G. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.10.007 · Cited by 337
“The recent development of mice with defined genetic lesions in lymph node-resident CD8a DC development (Hildner et al., 2008) may provide a framework to address these questions in more detail.”
Schneider, C., Nobs, S. P., Heer, A. K., Kurrer, M., Klinke, G., van Rooijen, N., Vogel, J., & Kopf, M. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004053 · Cited by 334
“129S(C)-Batf3/J (Batf3) mice [54] were purchased from the Jackson Laboratory.”
MethodAntigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Savage, P. A., Klawon, D. E. J., & Miller, C. H. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100219-020937 · Cited by 321
“(38) demonstrated that some Aire-dependent Treg cell clones failed to develop in Batf3−/− hosts, which exhibit a major reduction in Batf3-lineage CD8α+ cDCs (138).”
BackgroundGenetic Tracing via DNGR-1 Expression History Defines Dendritic Cells as a Hematopoietic Lineage
Schraml, B. U., van Blijswijk, J., Zelenay, S., Whitney, P. G., Filby, A., Acton, S. E., Rogers, N. C., Moncaut, N., Carvajal, J. J., & Reis e Sousa, C. (2013) · Cell · doi:10.1016/j.cell.2013.07.014 · Cited by 320
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 321
Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression
Huang, D., Wang, Y., Thompson, J. W., Yin, T., Alexander, P. B., Qin, D., Mudgal, P., Wu, H., Liang, Y., Tan, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00820-9 · Cited by 317
Dendritic cells as shepherds of T cell immunity in cancer
Pittet, M. J., Di Pilato, M., Garris, C., & Mempel, T. R. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.014 · Cited by 313
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche
Baldominos, P., Barbera-Mourelle, A., Barreiro, O., Huang, Y., Wight, A., Cho, J.-W., Zhao, X., Estivill, G., Adam, I., Sanchez, X., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.033 · Cited by 317
Studying the mononuclear phagocyte system in the molecular age
Chow, A., Brown, B. D., & Merad, M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3087 · Cited by 279
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Hewitt, S. L., Bai, A., Bailey, D., Ichikawa, K., Zielinski, J., Karp, R., Apte, A., Arnold, K., Zacharek, S. J., Iliou, M. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9143 · Cited by 316
Genetic models of human and mouse dendritic cell development and function
Anderson, D. A., Dutertre, C.-A., Ginhoux, F., & Murphy, K. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00413-x · Cited by 313
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity
Guo, C., You, Z., Shi, H., Sun, Y., Du, X., Palacios, G., Guy, C., Yuan, S., Chapman, N. M., Lim, S. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06299-8 · Cited by 304
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 312
Nikolos, F., Hayashi, K., Hoi, X. P., Alonzo, M. E., Mo, Q., Kasabyan, A., Furuya, H., Trepel, J., Di Vizio, D., Guarnerio, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29026-9 · Cited by 312
Esterházy, D., Loschko, J., London, M., Jove, V., Oliveira, T. Y., & Mucida, D. (2016) · Nature Immunology · doi:10.1038/ni.3408 · Cited by 311
Veglia, F., Tyurin, V. A., Mohammadyani, D., Blasi, M., Duperret, E. K., Donthireddy, L., Hashimoto, A., Kapralov, A., Amoscato, A., Angelini, R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02186-9 · Cited by 308
Desch, A. N., Randolph, G. J., Murphy, K., Gautier, E. L., Kedl, R. M., Lahoud, M. H., Caminschi, I., Shortman, K., Henson, P. M., & Jakubzick, C. V. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110538 · Cited by 304
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 305
“Indeed, mice deficient for Batf3, a transcription factor intricately involved in differentiation of cross-presenting DCs, are unable to evade tumor establishment [20].”
BackgroundAlcántara-Hernández, M., Leylek, R., Wagar, L. E., Engleman, E. G., Keler, T., Marinkovich, M. P., Davis, M. M., Nolan, G. P., & Idoyaga, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.001 · Cited by 301
“cDCs can be further divided into cDC1s and cDC2s with distinct lineage-specific TFs (Hildner et al., 2008; Schlitzer et al., 2013).”
Oxidized lipids block antigen cross-presentation by dendritic cells in cancer
Cao, W., Ramakrishnan, R., Tuyrin, V. A., Veglia, F., Condamine, T., Amoscato, A., Mohammadyani, D., Johnson, J. J., Min Zhang, L., Klein-Seetharaman, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302801 · Cited by 302
Lung Dendritic Cells in Respiratory Viral Infection and Asthma: From Protection to Immunopathology
Lambrecht, B. N., & Hammad, H. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075021 · Cited by 302
The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules
Cruz, F. M., Colbert, J. D., Merino, E., Kriegsman, B. A., & Rock, K. L. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055254 · Cited by 299
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 302
“To confirm the generality of these findings, we enforced PD-L1 expression in a second, unedited highly immunogenic MCA sarcoma line (H31m1) (28,43,44) (Fig.”
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Enamorado, M., Iborra, S., Priego, E., Cueto, F. J., Quintana, J. A., Martínez-Cano, S., Mejías-Pérez, E., Esteban, M., Melero, I., Hidalgo, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16073 · Cited by 293
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
How chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
“This DC subset is most effective at cross-presenting exogenous cell-associated antigens on MHC I proteins to CD8 + T cells, a critical function in CTL-mediated antitumour immunity 56,57 .”
Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life
Granot, T., Senda, T., Carpenter, D. J., Matsuoka, N., Weiner, J., Gordon, C. L., Miron, M., Kumar, B. V., Griesemer, A., Ho, S.-H., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.019 · Cited by 290
“…and specialize in cross-presentation to CD8+ T cells critical for immunity against intracellular pathogens, viruses, and cancer (Allan et al., 2003; Hildner et al., 2008; Pooley et al., 2001; Sung et al., 2006); and cDC2, which express CD11b and promote CD4+ T cell differentiation into subsets…”
BackgroundSegura, E., Durand, M., & Amigorena, S. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121103 · Cited by 288
“This conclusion is further supported by the shared requirement for the transcription factor Batf3 for the differentiation of both mouse CD8+ DCs and human BDCA3+ DCs (Hildner et al., 2008; Poulin et al., 2012).”
BackgroundHor, J. L., Whitney, P. G., Zaid, A., Brooks, A. G., Heath, W. R., & Mueller, S. N. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.020 · Cited by 285
Transcriptional programming of the dendritic cell network
Belz, G. T., & Nutt, S. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3149 · Cited by 282
“BATF3 was the first transcription factor that appeared to have an exclusive role in the development of the CD8α + DC”
BackgroundPerry, J. S. A., Lio, C.-W. J., Kau, A. L., Nutsch, K., Yang, Z., Gordon, J. I., Murphy, K. M., & Hsieh, C.-S. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.007 · Cited by 281
“BATF3deficiencywaspreviously reported to result in the lossof the CD8a DC subset by phenotypic markers and functional assays in the periphery (Hildner et al., 2008).”
InfluentialGajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC
Lauterbach, H., Bathke, B., Gilles, S., Traidl-Hoffmann, C., Luber, C. A., Fejer, G., Freudenberg, M. A., Davey, G. M., Vremec, D., Kallies, A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092720 · Cited by 278
“eCD8 cDCs have been identified based on their dependence on the transcription factors IRF8 or Batf3 to be present in several lymphoid and nonlymphoid organs (Hildner et al., 2008; Edelson et al., 2010).”
BackgroundResultInfluentialTissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276
“infected or transformed cells and to cross-present them on MHC-I in order to activate CD8 T cells [29, 31].”
Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 274
The STING pathway and the T cell-inflamed tumor microenvironment
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.003 · Cited by 271
“The requirement for type I IFN signaling was mapped to the level of APCs, and in particular to the Batf3-driven lineage DC subset, which encompasses DCs expressing CD8α or CD103 [44,50,51].”
BackgroundZelenay, S., Keller, A. M., Whitney, P. G., Schraml, B. U., Deddouche, S., Rogers, N. C., Schulz, O., Sancho, D., & Reis e Sousa, C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60644 · Cited by 272
Dendritic cells in cancer immunology
Murphy, T. L., & Murphy, K. M. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00741-5 · Cited by 269
Tewalt, E. F., Cohen, J. N., Rouhani, S. J., Guidi, C. J., Qiao, H., Fahl, S. P., Conaway, M. R., Bender, T. P., Tung, K. S., Vella, A. T., et al. (2012) · Blood · doi:10.1182/blood-2012-04-427013 · Cited by 270
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, A., Cueto, F. J., Garasa, S., Pérez-Gracia, J. L., Sánchez-Arráez, A., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267
Development and functional specialization of CD103+ dendritic cells
Del Rio, M., Bernhardt, G., Rodriguez‐Barbosa, J., & Förster, R. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00874.x · Cited by 266
“As splenic DCs or Flt3-treated BM-derived DCs from Batf3-deficient mice fail to express CD103 and 50–70% of splenic CD8a DCs coexpress CD103, it is tempting to speculate that CD103 DCs might require Batf3 for their development (77).”
BackgroundTolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263
Presentation of Phagocytosed Antigens by MHC Class I and II
Mantegazza, A. R., Magalhaes, J. G., Amigorena, S., & Marks, M. S. (2013) · Traffic · doi:10.1111/tra.12026 · Cited by 259
“This process is largely restricted to specific DC subsets in vivo (10,11), but can be replicated in other model cell types in culture.”
BackgroundNakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002852 · Cited by 257
Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation
Vander Lugt, B., Khan, A. A., Hackney, J. A., Agrawal, S., Lesch, J., Zhou, M., Lee, W. P., Park, S., Xu, M., DeVoss, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2795 · Cited by 254
Dendritic cells as gatekeepers of tolerance
Waisman, A., Lukas, D., Clausen, B. E., & Yogev, N. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0583-z · Cited by 250
Poulin, L. F., Reyal, Y., Uronen-Hansson, H., Schraml, B. U., Sancho, D., Murphy, K. M., Håkansson, U. K., Ferreira Moita, L., Agace, W. W., Bonnet, D., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406967 · Cited by 251
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Cross-presenting CD103+ dendritic cells are protected from influenza virus infection
Helft, J., Manicassamy, B., Guermonprez, P., Hashimoto, D., Silvin, A., Agudo, J., Brown, B. D., Schmolke, M., Miller, J. C., Leboeuf, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60659 · Cited by 249
Katlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 248
“Studies modeling sarcomas and melanomas in mice lacking the IFNAR1 chain of type I interferon (IFN) receptor suggest that endogenous IFNs contribute to anti-tumor immunity via stimulating specific CD8a lineage dendritic cells (DCs) to cross-present antigen to CTLs (Diamond et al., 2011; Fuertes et al., 2011; Hildner e…”
InfluentialTumor-infiltrating dendritic cell states are conserved across solid human cancers
Gerhard, G. M., Bill, R., Messemaker, M., Klein, A. M., & Pittet, M. J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200264 · Cited by 247
“More than 10 yr ago, mechanistic studies in mice uncovered Batf3 as a critical transcription factor for the production of DCs that cross-present antigens and participate in the elimination of immunogenic tumors (Hildner et al., 2008).”
BackgroundIntracellular mechanisms of antigen cross presentation in dendritic cells
Amigorena, S., & Savina, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.022 · Cited by 247
Dendritic cells and monocyte-derived cells: Two complementary and integrated functional systems
Schlitzer, A., McGovern, N., & Ginhoux, F. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.011 · Cited by 244
“Furthermore, the efficiency of uman CD1c+ DC in sensing viral infection is surprising, considering hat of the TLR able to detect virus-related PAMP only TLR8 is highly xpressed, with low expression of TLR3 and 7, and no expression f TLR9 [131,133].”
InfluentialBatf coordinates multiple aspects of B and T cell function required for normal antibody responses
Betz, B. C., Jordan-Williams, K. L., Wang, C., Kang, S. G., Liao, J., Logan, M. R., Kim, C. H., & Taparowsky, E. J. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091548 · Cited by 239
“Although a comparative profile of all AP-1 proteins expressed by various lymphocyte lineages has yet to be compiled, Batf and Batf3 are coexpressed in mouse Th1 cells, for example (Williams et al., 2001; Hildner et al., 2008).”
BackgroundTakagi, H., Fukaya, T., Eizumi, K., Sato, Y., Sato, K., Shibazaki, A., Otsuka, H., Hijikata, A., Watanabe, T., Ohara, O., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.10.014 · Cited by 238
“Although the cross-presentation of exogenous antigens in CD4 CD8a cDCs for the priming of CD8 T cells to elicit CTL immunity has been described (Dudziak et al., 2007; Hildner et al., 2008), the contribution of pDCs to this process in vivo”
BackgroundMethodInfluentialRodriguez-Ruiz, M. E., Rodriguez, I., Garasa, S., Barbes, B., Solorzano, J. L., Perez-Gracia, J. L., Labiano, S., Sanmamed, M. F., Azpilikueta, A., Bolaños, E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0549 · Cited by 238
Menares, E., Gálvez-Cancino, F., Cáceres-Morgado, P., Ghorani, E., López, E., Díaz, X., Saavedra-Almarza, J., Figueroa, D. A., Roa, E., Quezada, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12319-x · Cited by 237
Mundt, S., Mrdjen, D., Utz, S. G., Greter, M., Schreiner, B., & Becher, B. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8380 · Cited by 235
Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
Aznar, M. A., Tinari, N., Rullán, A. J., Sánchez-Paulete, A. R., Rodriguez-Ruiz, M. E., & Melero, I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601145 · Cited by 230
“More recent evidence suggests a key role for functionally specialized DC subsets, which are equipped to cross-present Ags to CTL precursors (12, 13).”
BackgroundThe Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer
Storozynsky, Q., & Hitt, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 228
“CD8α+ DCs are a subset of conventional DCs that require the Batf3 transcription factor (in mice) for development and exhibit efficient cross-presentation of viral and tumor antigens enabling CD8+ T cell-mediated defense [35,36].”
BackgroundLahoud, M. H., Ahmet, F., Kitsoulis, S., Wan, S. S., Vremec, D., Lee, C.-N., Phipson, B., Shi, W., Smyth, G. K., Lew, A. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101176 · Cited by 227
Bone-Marrow-Resident NK Cells Prime Monocytes for Regulatory Function during Infection
Askenase, M. H., Han, S.-J., Byrd, A. L., Morais da Fonseca, D., Bouladoux, N., Wilhelm, C., Konkel, J. E., Hand, T. W., Lacerda-Queiroz, N., Su, X.-Z., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.011 · Cited by 226
“01, this, in Batf3-deficient mice that are devoid of CD8a lymphoid resident DCs and migratory CD103CD11b DCs (Edelson et al., 2010; Hildner et al., 2008), IL-12p70 was not increased in the serum upon oral infection and early NK cell activation was not detected (Figures 6F–6H and S6H).”
InfluentialIPS-1 Is Essential for the Control of West Nile Virus Infection and Immunity
Suthar, M. S., Ma, D. Y., Thomas, S., Lund, J. M., Zhang, N., Daffis, S., Rudensky, A. Y., Bevan, M. J., Clark, E. A., Kaja, M.-K., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000757 · Cited by 224
“Analysis of CD8a DC subsets, which are phenotypically the major antigen presenting cells within lymphoid tissues and are implicated in eliciting virus-specific CD8 T cell in response to acute WNV infection [41] , showed that infected wild type and IPS-1 2/2 mice exhibited similar increases in the numbers of CD8a + and…”
Result
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.